GBS Ventures

GBS Venture Partners is a leading Australian venture capital firm specializing in life sciences. Founded in 1996, the firm is headquartered in Melbourne and focuses on early-stage investments in human therapeutics, biotechnology, diagnostics, and medical devices. GBS plays a critical role in advancing healthcare by backing companies that drive innovation in these sectors. They typically invest between $10M to $12M in companies that are poised to make a significant impact on patient care and deliver financial returns for their investors. Notable investments from GBS include Ivantis, Elastagen, and Moximed, companies focused on therapeutic devices and biotech advancements. GBS is hands-on, taking active board roles and working closely with management teams on corporate strategy, operations, and regulatory pathways. Their geographic focus is primarily Australia, though they also invest in the U.S. and Oceania. The firm is led by experienced professionals such as Brigitte Smith, a co-founder and managing partner. Smith brings decades of expertise in venture capital and healthcare innovation, ensuring that GBS maintains its strong track record in life sciences. Founders seeking investment should demonstrate a clear path to clinical and commercial success, as GBS is heavily invested in ensuring that startups have solid strategies for navigating complex healthcare markets.